Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by gebremeskelon Jan 09, 2025 12:24pm
157 Views
Post# 36396287

Interview with Carlyle's Stephen Wise

Interview with Carlyle's Stephen Wisehttps://www.pehub.com/carlyles-stephen-wise-the-market-is-set-up-well-for-exits-and-financing-new-deals/

"...In 2024, we executed several carve-outs, including Vantive and Worldpac, as strategics looked to optimize their capital deployment given a high-interest-rate environment. These transactions reflect out expertise in carve-outs, enabling us to unlock value and create operational efficiencies for the businesses we invest in. We expect to continue to see these opportunities, and have had success across many deal archetypes, including backing industry leaders, doing roll-ups and investing in high growth businesses.

What's your strategy on roll-ups?

We continue to view buy-and-builds as a key part of what we do, executing smart M&A to help grow businesses in core sectors while improving how they operate and setting them up for long term success. Within buy-and-builds, we focus on methodically selecting strategic targets, driving post-close integration, properly scaling the expense base and developing greater capabilities and offerings over time - not simply pursuing short-erm multiple arbitrage. We believe the best way to create long-term equity value is to build durable businesses that will be able to thrive (and that future buyers will want to acquire)."
<< Previous
Bullboard Posts
Next >>